Further acquisitions on gonadal function in bromocriptine treated hyperprolactinemic male patients.
The diurnal variation of plasma total and free testosterone (tT and fT) and the gonadotropinemic response to LH-RH were evaluated in a group of hyperprolactinemic impotent males with pituitary microprolactinoma before and during therapy with bromocriptine, a well known dopamine agonist drug. Before treatment, basal levels not only of tT but also of fT were decreased and the diurnal variation of both tT and fT was absent. Moreover, the LH-RH test showed a delay in the LH response peak, together with normal basal levels of LH. Bromocriptine therapy caused normalization of both the secretion response of LH to LH-RH and of the secretion pattern of tT and of fT (basal levels and diurnal variation) besides a significant decrease in PRL levels and an improvement in sexual function. The possible effects of high plasma levels of PRL at various levels of the hypothalamus-pituitary-testicular axis are discussed.
D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D002940:Circadian Rhythm; D007987:Gonadotropin-Releasing Hormone; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D007006:Hypogonadism / Q000097:blood* / Q000188:drug therapy / Q000209:etiology; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D013739:Testosterone / Q000097:blood*
D007987:Gonadotropin-Releasing Hormone; D001971:Bromocriptine; D013739:Testosterone; D007986:Luteinizing Hormone